Iovance Biotherapeutics (IOVA) Return on Sales (2023 - 2025)
Historic Return on Sales for Iovance Biotherapeutics (IOVA) over the last 6 years, with Q3 2025 value amounting to 1.35%.
- Iovance Biotherapeutics' Return on Sales rose 700.0% to 1.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.59%, marking a year-over-year increase of 29200.0%. This contributed to the annual value of 2.27% for FY2024, which is 3711700.0% up from last year.
- Per Iovance Biotherapeutics' latest filing, its Return on Sales stood at 1.35% for Q3 2025, which was up 700.0% from 1.86% recorded in Q2 2025.
- In the past 5 years, Iovance Biotherapeutics' Return on Sales ranged from a high of 1.07% in Q4 2024 and a low of 447.5% during Q2 2023
- Its 3-year average for Return on Sales is 110.07%, with a median of 2.74% in 2024.
- In the last 5 years, Iovance Biotherapeutics' Return on Sales surged by 4443800bps in 2024 and then surged by 700bps in 2025.
- Quarter analysis of 3 years shows Iovance Biotherapeutics' Return on Sales stood at 241.41% in 2023, then surged by 100bps to 1.07% in 2024, then decreased by -27bps to 1.35% in 2025.
- Its last three reported values are 1.35% in Q3 2025, 1.86% for Q2 2025, and 2.36% during Q1 2025.